Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Elephants do not avoid cancer entirely. But their cancer mortality appears lower than expected for animals of their size, and studies point to unusually strong cellular responses to DNA damage. Those defenses—especially signaling involving TP53 and the gene LIF6—offer clues about cancer biology, not a proven way to prevent or treat cancer in people.
Why elephants’ cancer risk is a scientific puzzle
Cancer develops when cells accumulate changes that let them grow and divide abnormally. Because large animals have many more cells, and long-lived animals have more time for cell damage to accumulate, a simple prediction would be that they should have much higher cancer risk than smaller, shorter-lived animals. Across species, however, cancer risk does not rise as simply as that prediction suggests. This puzzle is known as Peto’s paradox.
Elephants are one species scientists study to understand that mismatch. A 2015 comparative study examined necropsy records from 36 mammalian species, including 644 elephants. It estimated elephant cancer mortality at 4.81% (95% confidence interval, 3.14%–6.49%). That is a study estimate, not a universal rate for every elephant population, and it does not mean elephants never get cancer. The study’s methods and results provide the context for the figure.
How elephant cells respond to DNA damage
TP53 helps damaged cells stop or die
The gene TP53 encodes p53, a tumor-suppressor protein that helps cells respond to damage. Depending on the circumstances, p53 can help halt cell division or trigger apoptosis—the controlled death of a cell that should not keep multiplying.
#1 Best Overall
The 2015 study reported at least 20 TP53 copies in African elephants, including 19 retrogenes. Retrogenes are copies made from RNA and inserted back into the genome; they are not necessarily equivalent to ordinary, fully functional copies of the original gene. The study also exposed peripheral blood lymphocytes to DNA-damaging conditions and compared their apoptotic responses.
After ionizing radiation, apoptosis was measured in 14.64% of elephant lymphocytes, compared with 7.17% of healthy human control cells and 2.71% of cells from people with Li-Fraumeni syndrome, an inherited condition associated with impaired TP53 function and high cancer risk. After doxorubicin exposure, the measured figures were 24.77% for elephant lymphocytes and 8.10% for healthy human controls. These were in-vitro results from small groups—8 elephants, 11 healthy controls, and 10 people with Li-Fraumeni syndrome—not cancer rates or treatment outcomes.
Rank #2
Retrogenes may influence the damage response
A 2016 study proposed that elephant TP53 retrogenes contribute to heightened sensitivity to DNA damage by regulating TP53 signaling. That suggests the story is not simply “more copies of a cancer-fighting gene”: the copies may affect how the pathway responds, and their individual functions are not all established. The eLife study develops this mechanism.
LIF6 is another part of the proposed pathway
LIF6 is a separate gene implicated in the response. A University of Chicago Medicine research summary describes it as a formerly nonfunctional gene that gained a new regulatory switch. It is activated by p53 and produces a protein that moves to mitochondria, structures involved in energy production and cell-death signaling. The proposed role is to help damaged elephant cells undergo apoptosis. The university’s summary of the LIF6 findings outlines this account.
What is known—and what remains debated
The evidence comes from different kinds of studies, and those findings should not be treated as interchangeable. The mortality estimate is based on comparative necropsy records; the apoptosis results come from laboratory cell assays; and explanations for why these traits evolved are interpretations of evolutionary evidence.
A 2022 re-evaluation reported that the ancestral TP53 retrogene was already truncated and that many of the 19 African elephant copies are further truncated. That makes it inaccurate to say elephants simply have 20 working copies of the human cancer-suppressing gene. The re-evaluation indexed by PubMed challenges simple accounts of what those copies do.
Rank #4
A 2025 review argues that the expansion should also be considered in relation to reproduction and pleiotropy—the possibility that a gene affects more than one biological trait. This is an additional evolutionary interpretation, not a settled replacement for the DNA-damage findings. The 2025 review discusses those alternatives.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What elephant biology could mean for people
Comparative oncology—the study of cancer across species—can reveal biological pathways worth investigating. Elephant cell experiments make TP53 signaling, retrogenes, and LIF6 valuable subjects for further study. But the cited research does not show that adding elephant genes to people, mimicking their activity, or taking a supplement can safely prevent or treat human cancer.
Best Value
- The amazing bond between a boy and elephant that lasted a lifetime.
- Spans dozens of true life adventures and escapades.
- Gut-wrenching love story.
In short, elephants appear to have evolved cellular defenses that help limit cancer, but scientists are still working out how the pieces fit together. Their biology is a source of research questions, not a human prevention plan.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
